Rolf Günther to steer Bicycle Therapeutics
This article was originally published in Scrip
Executive Summary
Bicycle Therapeutics, the Cambridge, UK-based biotech firm that is developing a bicyclic peptide technology for the discovery of a new class of drug candidates with antibody-like selectivity and specificity but the potential for manufacturing at a similar cost to new chemical entities, has appointed Dr Rolf Günther as CEO. Previously, Dr Günther was CEO and COO of Affimed, where he will continue to serve as COO in a part-time role until August. Bicycle Therapeutics’ technology is based on discoveries made by its founders, Professor Christian Heinis and Sir Gregory Winter, at the MRC Laboratory of Molecular Biology in Cambridge.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.